Neurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Neurogene in a research note issued on Monday, April 29th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.19) per share for the quarter. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Neurogene's current full-year earnings is ($3.78) per share. Leerink Partnrs also issued estimates for Neurogene's Q3 2024 earnings at ($1.22) EPS, Q4 2024 earnings at ($1.23) EPS, FY2024 earnings at ($4.82) EPS, FY2025 earnings at ($4.43) EPS and FY2026 earnings at ($5.04) EPS.
Other research analysts have also issued research reports about the stock. TD Cowen initiated coverage on shares of Neurogene in a report on Thursday, January 4th. They set an "outperform" rating for the company. SVB Leerink started coverage on Neurogene in a research report on Monday. They issued an "outperform" rating and a $46.00 price objective for the company. William Blair started coverage on Neurogene in a research report on Thursday, March 21st. They set an "outperform" rating and a $61.00 target price on the stock. Stifel Nicolaus started coverage on Neurogene in a report on Friday, January 5th. They issued a "buy" rating and a $31.00 target price for the company. Finally, HC Wainwright boosted their price target on Neurogene from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, March 19th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $48.25.
Read Our Latest Analysis on NGNE
Neurogene Price Performance
Shares of NGNE traded up $1.62 during mid-day trading on Thursday, reaching $35.39. 78,640 shares of the company were exchanged, compared to its average volume of 124,832. The stock has a 50 day simple moving average of $38.19. Neurogene has a 52 week low of $12.20 and a 52 week high of $53.00. The company has a market capitalization of $455.47 million, a PE ratio of -2.84 and a beta of 1.37.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in NGNE. Great Point Partners LLC acquired a new position in shares of Neurogene during the fourth quarter valued at about $19,268,000. Avidity Partners Management LP bought a new stake in Neurogene during the 4th quarter worth approximately $9,036,000. BML Capital Management LLC purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $478,000. Finally, Privium Fund Management UK Ltd purchased a new stake in shares of Neurogene in the first quarter worth approximately $274,000. Institutional investors own 52.37% of the company's stock.
Neurogene Company Profile
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
